A Comparison Between Lidocaine and remimazolam on the Prevention of propofol Injection pain during genel anesthesiology

Comparison Between Lidocaine and remimazolam on the Prevention of propofol Injection pain during genel anesthesiology

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039704

Enrollment

Unknown

Registered

2020-11-06

Start date

2020-11-06

Completion date

Unknown

Last updated

2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Injection pain

Interventions

Control group:Saline intravenous injection

Lidocaine group:Lidocaine intravenous injection

Remimazolam group:Remimazolam intravenous injection

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-60 years old; 2. Asa1-ii patients; 3. Patients scheduled for elective general anesthesia.

Exclusion criteria

Exclusion criteria: 1. Patients with liver and kidney dysfunction; 2. Patients allergic to the study drug; 3. Patients with nervous system or cardiovascular diseases or obese patients; 4. Patients with difficult airway; 5. Pregnant and lying in women; 6. Patients taking analgesics.

Design outcomes

Primary

Measure	Time frame
Pain;	—

Secondary

Measure	Time frame
intensity of pain;	—

Countries

China

Contacts

Public ContactXuehai Guan

The First Affiliated Hospital of Guangxi Medical University

guan_xh@aliyun.com+86 18587697310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026